Bioxyne on Track to Report Clinical Trial Results in June
News May 29, 2012
Bioxyne Limited has confirmed that it is on track for the release of data from its Phase IIb trial as scheduled in June.
The Company confirmed the 320-patient study to evaluate the efficacy and safety of the Bioxyne’s HI-164OV therapy for patients with chronic obstructive pulmonary disease (COPD) had been closed and that data was in the late stages of analysis.
The primary aim of the study is to assess the impact of treatment with HI-164OV in reducing severe exacerbations in COPD patients and reducing the need for admission to hospital.
There are a number of measures of disease severity being examined which will define the profile and benefits of HI-164OV and its potential long term value.
Bioxyne Chief Executive Officer David Radford said, “We are focused on ensuring accurate communication of the trial results and to also guard against partial and incomplete reporting of the results.
“Given the importance of the results, Bioxyne may consider a short-term trading halt during the period between our receipt of initial data through until the time when the Company has formally assessed the final result and is able to accurately communicate these results to the market.
The primary endpoint in the trial is a demonstration of a reduction in exacerbations requiring oral corticosteroid treatment or hospitalization.
The secondary endpoints seek to determine if HI-164OV can reduce the severity of exacerbations, the number of patients experiencing exacerbations requiring corticosteroid treatment or hospitalization and a reduction in the use of antibiotics and or corticosteroids.
There have been no indications of patient related safety issues during the trial.
Investigational Drug for Melanoma Shows Promise in Early-Stage StudyNews
An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial researchers have reported.READ MORE
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018